NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-NS-20-033 from the NIH Guide for Grants and Contracts
Notice NOT-NS-20-032 from the NIH Guide for Grants and Contracts
Notice NOT-NS-20-031 from the NIH Guide for Grants and Contracts
Notice NOT-NS-20-030 from the NIH Guide for Grants and Contracts
Notice NOT-NS-20-029 from the NIH Guide for Grants and Contracts
Notice NOT-DE-20-005 from the NIH Guide for Grants and Contracts
Notice NOT-DE-20-004 from the NIH Guide for Grants and Contracts
Notice NOT-DA-20-012 from the NIH Guide for Grants and Contracts
Notice NOT-DA-20-007 from the NIH Guide for Grants and Contracts
Notice NOT-AA-19-034 from the NIH Guide for Grants and Contracts
Notice NOT-CA-20-021 from the NIH Guide for Grants and Contracts
Notice NOT-NS-20-013 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-20-055 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states.
Funding Opportunity PAR-20-082 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states.
Notice NOT-NS-20-036 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-19-029 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing original research addressing barriers that limit progress toward effective open- and closed-loop glucose control systems. Proposed research should tackle important obstacles at the level of sensing, hormone formulation and delivery, self-management decision support systems, and/or design of automated controllers/algorithms able to manage an integrated platform. This research may contribute to development of affordable and user friendly technologies to improve glucose control in patients with type 1 diabetes.
Funding Opportunity RFA-DK-19-026 from the NIH Guide for Grants and Contracts. The New Investigator Gateway Award in T1D Research is designed to ensure that a robust pipeline of talented new investigators will continue to embark on successful careers in T1D research. In addition to providing support for preliminary research, the Gateway program provides an opportunity for new PIs to pursue their studies within the intellectual environment of a select number of large, ongoing collaborative research programs. Embedding awardees within an established scientific framework in each of these consortia will provide unique opportunities for New andEarly Stage Investigators to increase their understanding of key questions in the field, to network, and to establish unique and potentially long-lasting collaborations that will propel their careers forward.
Funding Opportunity RFA-DK-19-024 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) requests applications to explore human pancreatic tissues for the discovery of specific signaling or processing pathways that may contribute to the asymptomatic phase of T1D, the discovery of early biomarkers of T1D pathogenesis, the development of diagnostic tools for the detection and staging of early T1D in at-risk or recently-diagnosed individuals, and/or the identification and biological validation of therapeutic targets for the development of preventative or early treatment strategies. Successful applicants will join the Consortium on Beta Cell Death and Survival (CBDS), whose mission is to better define and detect the mechanisms of beta cell stress and destruction central to the development of T1D in humans, with the long-term goal of protecting the residual beta cell mass in T1D patients as early as possible in the disease process, and of preventing the progression to autoimmunity. The CBDS is part of a collaborative research framework, the Human Islet Research Network (HIRN, https://hirnetwork.org ), whose overall mission is to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional beta cell mass in humans. This FOA will only support studies with a primary focus on increasing our understanding of human disease biology (as opposed to rodent or other animal models). This FOA will not accept applications proposing a clinical trial.
Funding Opportunity RFA-DK-19-021 from the NIH Guide for Grants and Contracts. This FOA seeks applications for clinical trials testing interventions targeting diabetes distress in individuals with type 1 diabetes and/or their caregivers, with the goal of understanding whether lowering diabetes distress will improve glycemic control and quality of life. Given the clinical care recommendation that screening for diabetes distress take place in the context of medical care, applications should reflect a practical team approach to screening and treatment that could realistically occur in a clinical setting.
Notice NOT-OD-20-054 from the NIH Guide for Grants and Contracts